

Cite this: *J. Mater. Chem. B*, 2023, 11, 9516

# Dual ligand-assisted assembly of metal–organic frameworks on upconversion nanoparticles for NIR photodynamic therapy against hypoxic tumors†

Xinyue Zhang,<sup>‡,a</sup> Jiasen Cui,<sup>‡,b</sup> Jinhui Liu,<sup>a</sup> Xi Chen,<sup>b</sup> Mingli Chen<sup>‡,\*a</sup> and Jianhua Wang<sup>‡,\*a</sup>

The hypoxic nature of tumor microenvironments significantly impedes the effectiveness of photodynamic therapy (PDT). To address this challenge, we constructed a pioneering nanohybrid by integrating upconversion nanoparticles (UCNPs) and metal–organic frameworks (MOFs) through a dual-ligand-assisted assembly approach. We functionalized UCNPs with polyvinyl pyrrolidone (PVP) and branched polyethylenimine (PEI), enabling the *in situ* growth of MOFs on multiple UCNP-conjugates. This nanohybrid, termed UCM, possesses a unique heterogeneous structure that facilitates effective energy transfer from UCNPs to MOFs, enhancing NIR-activated PDT. A distinguishing feature of UCMs is biocatalytically active MOFs, which provide them with a peroxidase-like capability. This characteristic allows UCMs to utilize the excess H<sub>2</sub>O<sub>2</sub> in the tumor microenvironment, ensuring continuous oxygen production essential for type II PDT. Our research indicates that UCMs not only amplify the efficacy of PDT but also address the therapeutic challenges in hypoxic tumor microenvironments by supplying *in situ* oxygen.

Received 20th June 2023,  
Accepted 7th September 2023

DOI: 10.1039/d3tb01398g

rsc.li/materials-b

## 1. Introduction

Malignant tumors pose a significant threat to human lives, with an increasing incidence.<sup>1,2</sup> Photodynamic therapy (PDT) is a precise cellular-level treatment that relies on the photoactivation of photosensitizers (PS) to generate reactive oxygen species (ROS), leading to therapeutic effects and cancer cell death. ROS disruption of tumor metastasis homeostasis induces severe apoptosis in tumor cells, effectively halting tumor progression.<sup>3–5</sup> Metal–organic frameworks (MOFs) have gained extensive applications in biomedical fields due to their tunable functionality and favorable biocompatibility.<sup>6–11</sup> In particular, MOFs can integrate photosensitizers into periodic arrays and self-assemble porphyrins and metal ions through coordination, enabling high photosensitizer loading. The unique structure of MOFs prevents photosensitizer aggregation and enhances

photodynamic therapy efficiency.<sup>12–14</sup> The type II PDT mechanism typically involves an energy transfer process, where the photosensitizer in the triplet state transfers energy directly to the surrounding oxygen, generating cytotoxic singlet oxygen (<sup>1</sup>O<sub>2</sub>). However, PDT exacerbates tumor hypoxia, thereby diminishing its efficacy.<sup>15</sup> Intriguingly, certain characteristics of the tumor microenvironment present opportunities to augment therapeutic outcomes. For instance, the tumor milieu is often replete with hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). Some researchers have harnessed the metal-mediated Fenton reaction to decompose H<sub>2</sub>O<sub>2</sub>, generating toxic hydroxyl radicals, thereby synergistically enhancing antitumor effects.<sup>16</sup> Alternatively, leveraging peroxidase-mimetic activity to decompose H<sub>2</sub>O<sub>2</sub>, leading to *in situ* oxygen generation, offers a promising avenue to bolster the efficacy of photodynamic therapy.<sup>17–19</sup> Conventional porphyrin MOFs lack central metals with redox activity and exhibit no biocatalytic properties. To address this, Fe(III)–porphyrin can be employed as an organic ligand, enabling Fe<sup>3+</sup> to serve as an active metal center. The resulting iron–porphyrin MOFs can act as biocatalysts, catalyzing H<sub>2</sub>O<sub>2</sub> (50–100 μM) within the tumor microenvironment to alleviate hypoxia.<sup>20,21</sup>

MOFs as photosensitizers require photoirradiation to initiate photodynamic therapy. However, in living organisms, the weak penetration capability of visible light to tissues significantly limits the therapeutic depth of MOFs and weakens the

<sup>a</sup> Department of Chemistry, Northeastern University, Box 332, Shenyang 110819, China. E-mail: chenml@mail.neu.edu.cn, jianhuaqrz@mail.neu.edu.cn; Fax: +86 24 83676698; Tel: +86 24 83688944

<sup>b</sup> School and Hospital of Stomatology, Department of Oral Pathology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang, 110001, China

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3tb01398g>

‡ These authors contributed equally to this study.

photodynamic treatment effect.<sup>22–25</sup> Near-infrared light (NIR) provides deeper penetration capability in tissues, and thus it is highly desired to develop a NIR activated photodynamic therapy platform. Photostimulated luminescence involves the release of stored energy from a previously excited state when exposed to light, leading to the emission of luminescence. In contrast, upconversion refers to the process of absorbing two or more photons to emit light at a shorter wavelength. This process typically converts near-infrared or infrared light to visible or ultraviolet light, exhibiting potential intra-biological photomodulation and photoconversion.<sup>26–28</sup> In this respect, the integration of UCNPs with MOFs provides a promising avenue for improving the efficiency of PDT. UCNPs receive near-infrared photons to enable energy transfer to MOFs *via* FRET and initiate NIR activated PDT. Recently, a number of UCNP-MOF composites with a heterogeneous structure have emerged and found wide applications in photodynamic therapy, targeted drug delivery, bioassay and bioimaging.<sup>29–32</sup> The fundamental studies have demonstrated that a key issue in the synthesis of MOF crystals is to regulate the deprotonation of the organic ligands in order to control the reaction rate with metal ions.<sup>33</sup> In this respect, the synthesis of MOFs in a homogeneous medium is used to control the nucleation and crystal growth, which is a competitive process with the assembly of UCNPs-MOFs in a heterogeneous medium. Therefore, it is critical to functionalize UCNPs with various functional moieties for endowing them with specific surface properties to initiate the growth of MOFs on the UCNP surface.

In this study, we constructed novel UCNP-MOF nanohybrids (UCMs) with asymmetric hetero structures by employing the so-called dual-ligand-assisted self-assembly strategy. The two ligands, *i.e.*, polyvinyl pyrrolidone (PVP) and branched polyethyleneimine (PEI), promote heterogeneous nucleation and enable *in situ* growth of iron porphyrin-based MOFs [PCN-224(Fe)] on multiple UCNPs. Porphyrin-based MOFs exhibit great potential as photosensitizers for PDT. The integration of UCNPs with PCN-224(Fe) ensures deeper tissue treatment. In addition, PCN-224(Fe) possesses peroxidase-like activity and catalyzes the breakdown of endogenous H<sub>2</sub>O<sub>2</sub> in tumors to produce oxygen and alleviate hypoxia in the tumor micro-environment. By taking advantage of the absorption of NIR by UCNPs and the biocatalytic activity of PCN-224(Fe), the obtained UCMs nanohybrids serve as a multifunctional platform for synergistic NIR-activated PDT to show excellent anti-tumor capability for both *in vitro* and *in vivo* treatments.

## 2. Experimental

### 2.1. Preparation of UCNPs, PEI/PVP-UCNPs and UCMs

In a typical procedure, 1.0 mmol of LnCl<sub>3</sub>·6H<sub>2</sub>O (Ln = Y, Yb, Tm, Nd) was mixed with 6 mL of oleic acid and 15 mL of octadecene. The mixture solution was heated to 160 °C with stirring under argon and kept at 160 °C for 60 min to remove oxygen and water. The solution was cooled to room temperature. Then a 10 mL methanol solution of NaOH (2.5 mmol) and NH<sub>4</sub>F

(4.0 mmol) was added dropwise and stirred for another 60 min. The solution mixture was heated to 120 °C, kept at this temperature for another 60 min to remove methanol and then heated to 300 °C and maintained for 60 min under an argon atmosphere. The products were centrifuged and washed three times with cyclohexane solution. The final products were stored in cyclohexane. Basic surface modification of the as-synthesized NaYF<sub>4</sub>:25% Yb<sup>3+</sup>, 0.9% Tm<sup>3+</sup>, 0.6% Nd<sup>3+</sup> nanocrystals with PEI, was performed by the widely accepted solvent evaporation method described elsewhere.<sup>34</sup> In brief, the branched PEI (300 mg) was added to the chloroform dispersion of OA-UCNPs (10 mg mL<sup>-1</sup>, 6 mL). The mixture was sonicated in an ultrasonic bath for 10 min and then stirred for 4 h at room temperature. After evaporation of the solvent, the resulting residue was added to ethanol. After further sonication, the resulting dispersion was stirred vigorously at room temperature for 1 h. Then, PVP (600 mg) was added to the obtained solution, subjected to ultrasonic treatment for 10 minutes, and the mixed solution was stirred for 24 h. Centrifuge the reacted solution and wash it three times with ethanol.

Add Fe(III)-TCPP (4 mg) and ZrCl<sub>4</sub> (4 mg) into a mixture solution of dmf/ethanol/methanol (2 mL/1 mL/1 mL), then add PEI/PVP-UCNPs (8 mg) and sonicate the mixed solution for 10 minutes. Further, add glacial acetic acid (400 μL) to the mixed solution. Continue stirring the mixed solution at room temperature for 4 h. Afterwards, benzoic acid (35 mg) was added, stirring continued, and the mixture was heated to 90 °C to conduct the reaction for another 5 h. Finally, the product was washed and obtained by centrifugation.

### 2.2. Cellular uptake of UCMs

HepG2 cells were cultured overnight in confocal dishes, the original medium was removed. DMEM medium solution containing UCMs (100 μg mL<sup>-1</sup>) was added, and the cells continued to incubate for 15, 30, 60 and 120 min. The medium was then removed, and DMEM medium containing DAPI was added. After incubation at 37 °C for various times, the medium was removed, the cells were washed three times with PBS, and the cells were observed under a confocal laser scanning microscope. UCMs were excited by a 488 nm laser and the red emission from the porphyrin-MOF was collected using a band-pass filter within the range 600–700 nm.

### 2.3. Cell photodynamic therapy experiments

CCK-8 assay, dead and live cell staining assay and flow cytometry were used to determine the capability of UCMs to inhibit the growth of tumor cells. For CCK-8 experiments, to simulate the tumor hypoxic environment, HepG2 cells were incubated in oxygen-depleted bags. HepG2 cells were seeded into 96-well plates and cultured for 24 h. Thereafter the original medium was removed, and the cells were treated with UCMs (with or without 100 μM H<sub>2</sub>O<sub>2</sub>). The cells were then divided into two groups, *i.e.*, treated with or without laser at 980 nm at 1.5 W cm<sup>-2</sup>. The cells were then incubated for 4 h to ensure that UCMs was internalized and phagocytosed by the cells. The cells were irradiated with laser for 10 min. After 24 h of further

incubation, 10  $\mu\text{L}$  of CCK-8 solution was added, and the relative cell viability was determined using a microplate reader.

For the dead and live cell staining assay, the HepG2 cells were incubated for 24 h, and then the original medium was replaced with DMEM containing different components ( $\text{H}_2\text{O}_2$ , UCMs or UCMs +  $\text{H}_2\text{O}_2$ ) and incubated for another 4 h. The treated cells were divided into two groups. The irradiation group was irradiated using a 980 nm laser ( $1.5 \text{ W cm}^{-2}$ ) for 10 min. Then the cells were washed with PBS and stained with FDA (10  $\mu\text{M}$ ) and PI (20  $\mu\text{M}$ ) simultaneously. After staining for 20 min, the medium was removed and washed with PBS. Finally, fluorescence imaging of cells was performed by CLSM.

For flow cytometry analysis of apoptosis, HepG2 cells were treated by using the above FDA/PI assays. Then, the treated cells were dissociated for 2 min, and were collected by centrifugation. Afterwards, 500  $\mu\text{L}$  of binding buffer was added to the re-disperse the cells, and then the PBS solution containing Annexin V (5  $\mu\text{L}$ ) and PI (5  $\mu\text{L}$ ) were utilized to dye the live and dead cells for 30 min. Finally, the apoptosis ratio of tumor cells after different treatments were analyzed by flow cytometry.

#### 2.4. *In vivo* anticancer effect

The HepG2 tumor model was constructed by a subcutaneous injection of HepG2 cells into the dorsal flank of mice. Tumor-bearing mice were collected until the tumor volume reached about 200–400  $\text{mm}^3$ , and then used for *in vivo* antitumor therapy. Tumor volume = (tumor length)  $\times$  (tumor width)<sup>2</sup>/2. The relative tumor volume was calculated as  $V_t/V_0$ . ( $V_t$  and  $V_0$  represent the tumor volume at the end and the beginning of the treatment, respectively).

HepG2 tumor-bearing mice were randomly divided into four groups (3 mice in each group), and treated with PBS, PBS with laser, UCMs, UCMs with laser *via* a tail-vein injection. UCMs were injected intravenously at a concentration of 4  $\text{mg mL}^{-1}$  (100  $\mu\text{L}$ ), and the 980 nm laser ( $1.5 \text{ W cm}^{-2}$ , 10 min, 2 min break after 2 min irradiation) was used for the irradiation of tumors at 8 h post-injection. After each two days, another injection and treatment were applied using the same parameters. During antitumor treatment in mice, the tumor size and the body weights were measured and recorded every other day by using Vernier calipers and an electronic balance. After 14 days of treatment, the mice were euthanized, and their tumor tissues were harvested and weighed. The collected major organs (lungs, liver, spleen, and kidneys) were sectioned and stained with hematoxylin and eosin (H&E) for histological analysis. In addition, tumor tissue was sectioned and stained with Ki67 and ALDH1 for histological analysis.


Furthermore, hypoxia *in vivo* was tested using HIF-1 $\alpha$ . At first, the extracted tumors of mice were divided into two groups, including tail-vein injection of saline as a blank group, and tail-vein injection of UCMs (4  $\text{mg mL}^{-1}$ , 100  $\mu\text{L}$ ). Next, the frozen sections were dyed using HIF-1 $\alpha$  and DAPI. Finally, the tumor slices of each group were observed by CLSM.

## 3. Results and discussion


### 3.1. Preparation and characterizations of UCNPs and UCMs

UCNPs ( $\text{NaYF}_4:25\% \text{ Yb}^{3+}$ , 0.9%  $\text{Tm}^{3+}$ , 0.6%  $\text{Nd}^{3+}$ ) were first prepared in a mixed solution containing oleic acid and octadecene with thermal decomposition.<sup>35</sup> UCNPs were then sequentially modified with dual-ligands, *i.e.*, PEI and PVP. Thereafter, the controlled assembly of PCN-224(Fe) on multiple UCNPs was conducted for *in situ* growth and thermal crystallization to obtain UCMs. The process for the preparation of UCMs and the potential mechanisms of type II photodynamic therapy treatment in hypoxic microenvironment are illustrated in Scheme 1.

Fig. 1a illustrates that the obtained UCNPs were well dispersed with favorable homogeneity and size distribution at  $\sim 32.7 \text{ nm}$ . Afterwards, the hydrophobic UCNPs were modified with PEI to convert into hydrophilic and disperse in PVP solution, wherein the PVP moiety can continuously attach to UCNPs. The hexagonal nanostructure of UCNPs was almost unchanged when two layers of ligands were covered on UCNPs with an average size of  $\sim 37.8 \text{ nm}$  (Fig. 1b). Ligand exchange led to no obvious aggregation of UCNPs which were well dispersed in aqueous medium. The synthesis process for the heterogeneous structured UCMs was observed by TEM images in Fig. S1 (ESI<sup>†</sup>). PEI/PVP-modified UCNPs were mixed with PCN-224(Fe) precursors, *i.e.*,  $\text{ZrCl}_4$  and Fe(III)-TCPP, in a specific ratio of dmf/ethanol/methanol. The double-ligand modification of UCNPs drove the onset of heterogeneous nucleation process under the catalysis of acetic acid. After 5 min of mixing, the presence of many clusters of free MOFs in the solution may be clearly observed (Fig. S1b, ESI<sup>†</sup>), and a layer of MOFs could be identified on the surface of UCNPs. After 4 h of mixing, larger



Scheme 1 Illustration for the dual ligand functionalization of UCNPs and MOF assembly on multiple UCNPs to obtain the nanohybrid UCMs, and the potential mechanisms by employing UCMs in type II PDT treatment against cancer cells in a hypoxic microenvironment.



**Fig. 1** TEM images of (a) UCNP (NaYF<sub>4</sub>:25% Yb<sup>3+</sup>, 0.9% Tm<sup>3+</sup>, 0.6% Nd<sup>3+</sup>), (b) dual-ligand PEI/PVP modified UCNP, and (c) UCM. (d) SEM images of UCM. (e) Dark-field TEM images and the corresponding area-elemental mapping of UCMs, including Zr, Fe, Y and Yb. (f) The statistical data showing the size distributions of OA-UCNPs, PEI/PVP-UCNPs and UCMs. (g) FT-IR spectra for OA-UCNPs, PEI/PVP-UCNPs and UCMs. The scale bars indicate 50 nm in all the tested cases.

heterogeneous clusters of irregular morphology were formed on the surface of UCNP (Fig. S1c, ESI<sup>†</sup>). Then the heterogeneous clusters on the surface of UCNP were further thermally crystallized under thermodynamic drive (Fig. S1(d)–(f), ESI<sup>†</sup>), wherein it indicated that the growth size of PCN-224(Fe) may be well regulated by controlling the thermal crystallization time. For the construction of heterostructures, it is important to manipulate the surface properties of the heterogeneous nucleation interface to create the required conditions for triggering heterogeneous nucleation.<sup>36</sup> On the one hand, PEI possesses –NH<sub>2</sub> functional groups to facilitate the enrichment of Fe(III)–TCPP to the nucleation surface through an amide reaction.<sup>37</sup> On the other hand, PVP is capable for chelating metal ions,<sup>29</sup> and thus the co-modification of PVP and PEI create heterogeneous nucleation sites on UCNP. In addition, both PEI and PVP ligands can drive multiple UCNP aggregates to further expand heterogeneous nucleation sites. When only PEI modification is available, multiple MOFs are generated on the surface of UCNP to initiate irreversible aggregation (Fig. S2a, ESI<sup>†</sup>). When only PVP modification was performed, multiple MOFs grew on the surface of UCNP simultaneously (Fig. S2e, ESI<sup>†</sup>). In contrast, moderate growth of single MOFs on the surface of multiple UCNP allows for better energy transfer between heterogeneities.<sup>38</sup> By changing the addition ratio of PEI and PVP (Fig. S2(b)–(d), ESI<sup>†</sup>), the dual-ligand co-modification further expanded the heterogeneous nucleation sites and provided a suitable growth environment for the regular growth of MOFs, resulting in heterogeneous UCMs with good dispersion and uniform morphology. Thermogravimetric analysis was performed on different UCNP to analyze the quantity of modified ligands on the surface of UCNP. The results illustrated sequential increment on the loss of the

sample weight, which indicated the continuous attachment of the dual ligands on the surface of the UCNP. The modified amount of ligands on the UCNP was derived to be *ca.* 4.8% and *ca.* 4.4% for PEI and PVP, respectively (Fig. S4, ESI<sup>†</sup>). The addition of methanol is necessary for the self-assembly of UCMs.<sup>39</sup> The solvent likewise affects the heterogeneous growth environment, and the PCN-224(Fe) growth morphology is transformed from longitudinal rods to ellipsoidal crystals of appropriate size by continuously changing the methanol concentration (Fig. S3a and b, ESI<sup>†</sup>). Irregular Zr-TCPP products were generated on the surface of UCNP when no DMF was introduced into the reaction environment. (Fig. S3c, ESI<sup>†</sup>). In addition, it was verified that the heterostructure was not affected by the electrostatic force effect. The upconversion luminescence on the UCMs did not recover in the presence of different concentrations of NaCl. This observation well indicated the favorable structural stability of UCMs, which encountered no heterostructure separation at the ionic strength of the solution (Fig. S5, ESI<sup>†</sup>).

UCMs with asymmetric structures were clearly identified from the TEM images as illustrated in Fig. 1c. Meanwhile, the morphology of PCN-224(Fe) was found to remain unchanged (Fig. S6, ESI<sup>†</sup>). This well indicated the stabilization effect of dual-ligand by *in situ* growth on the surface of UCNP (Fig. 1d). TEM images of the UCMs and elemental mapping of their corresponding regions confirmed the asymmetric nanostructure of the UCMs (Fig. 1e). The size of the UCMs was derived to be *ca.* 122.1 nm (Fig. 1f). The elemental mapping images in Fig. 1e further indicated that the representative elements Y and Yb of UCNP were distributed only in the area on the MOF side, while the elements Zr and Fe of MOFs were uniformly distributed throughout the NPs. This observation indicated the tight *in situ* growth of MOFs on the surface of UCNP. The standard cards of OA-UCNP and PEI/PVP-UCNP with β-NaYF<sub>4</sub> were well indexed according to the X-ray diffraction (XRD) patterns of different samples (Fig. S7, ESI<sup>†</sup>) (JCPDS: 16-0334). When the asymmetric UCNP-MOFs nanostructures were formed, the XRD patterns of UCMs showed two new peaks at 7.1° and 9.9°, respectively. These peaks well matched the simulated curve of PCN-224(Fe), which indicated the successful synthesis of UCMs. In addition, zeta potential values in different steps were recorded to evaluate the formation of nanoparticles with different components. It revealed the potential variation throughout the reaction, and this provided further evidence for the synthesis of UCMs (Fig. S8, ESI<sup>†</sup>). Furthermore, we analyzed the surface chemistry of UCMs by X-ray photoelectron spectroscopy (XPS), and the characteristic elements Y, Zr and Fe of UCNP and PCN-224(Fe) could be well found from the XPS full spectrum (Fig. S9a, ESI<sup>†</sup>). Fig. S9(b)–(e) (ESI<sup>†</sup>) illustrates that the C 1s spectrum was deconvoluted into three peaks at 284.8, 286.5, and 288.4 eV, which can be attributed to C=C, C–C/C–H, and C=O/C=N, respectively. The deconvolution of N 1s and Fe 2p spectra derived the characteristic peaks of Fe–N,<sup>40</sup> and C–N attributed to porphyrin iron located at 712.3 eV, 725.1 eV and 399.2 eV. In the O 1s spectrum, the C=O peak located at 533.05 eV is obviously stronger than the

C–O peak at 534.7 eV, and the characteristic O=C–N peak was identified at 401.3 eV. This observation indicated the successful reaction of porphyrin with the imine group. FT-IR spectra in Fig. 1g indicate that the modified dual-ligand UCNP showed a typical C=O stretching peak at 1673.9  $\text{cm}^{-1}$  and a C–N characteristic stretching vibration peak at 1290.1  $\text{cm}^{-1}$  in comparison with OA-UCNPs. In addition, the modification of dual-ligands significantly weakened the characteristic  $-\text{CH}_3$  peak, which further demonstrated the assembly of the dual ligands on OA-UCNPs. In the FT-IR spectra of UCMs, the sharp characteristic bands (C=O) at 1631.7  $\text{cm}^{-1}$  and 1606  $\text{cm}^{-1}$ , the enhancement of the characteristic band (N–H) at 3400  $\text{cm}^{-1}$  and the weakening of the characteristic band (C–N) at 1290  $\text{cm}^{-1}$  clearly indicated that the porphyrin monomer reacted with the amine group on the surface of UCNP by condensation. These observations well demonstrated *in situ* growth of the MOFs on the surface of UCNP.

### 3.2. Photodynamic properties of UCMs

The upconversion luminescence properties of UCNP were investigated. Under 980 nm laser irradiation, the upconversion luminescence spectra are shown in Fig. 2b, emitting mainly short-wavelength light centered at 450 nm ( $^1\text{D}_2 \rightarrow ^3\text{F}_4$ ), 475 nm

( $^1\text{G}_4 \rightarrow ^3\text{H}_6$ ) and 645 nm ( $^1\text{G}_4 \rightarrow ^3\text{F}_4$ ) and 700 nm ( $^3\text{F}_3 \rightarrow ^3\text{H}_6$ ) (as shown in Fig. S10, ESI $^\dagger$ ). It is obvious that the upconversion luminescence intensity of UCNP after modification with dual-ligands is not significantly weakened with respect to that of OA-UCNP (Fig. 2b). Fig. 2a indicates that UCMs present a typical broad UV-vis absorption band for PCN-224(Fe) within the range of 300–650 nm. The overlap of absorption spectra and upconversion spectra may indicate the possibility of energy resonance transfer between PCN-224(Fe) and UCNP. The intensity of the upconversion luminescence spectra of UCMs was significantly decreased compared to that of PEI/PVP-UCNP (Fig. 2b). This observation provided an indication for the energy transfer process in heterogeneous structures of UCMs. To further verify the occurrence of energy transfer, time-resolved photoluminescence lifetimes were investigated for PEI/PVP-UCNP and UCMs. As shown in Fig. S11 (ESI $^\dagger$ ), the decay curves show a significant decrease in the lifetime of  $\text{Tm}^{3+}$  emission from 443.9  $\mu\text{s}$  to 366.6  $\mu\text{s}$  at 475 nm and from 457.1  $\mu\text{s}$  to 362.6  $\mu\text{s}$  at 645 nm. Thus, UCNP can harvest low-energy photons in the NIR light region to produce emission at short wavelengths, which can be resonated by fluorescence resonance energy transfer (FRET) absorbed by PCN-224(Fe). Due to the presence of the porphyrin ligand, PCN-224(Fe) can generate  $^1\text{O}_2$  under 660 nm light irradiation.<sup>12</sup> Therefore, in the UCM system, the activated porphyrin ligand can effectively absorb energy-delivering light and generate toxic  $^1\text{O}_2$  to facilitate photodynamic type II treatment.

For investigating the capability of UCMs for the production of  $^1\text{O}_2$  with excitation by NIR irradiation, 9,10-anthracenediyl-bis(methylene)dimalonic acid (ABDA) was used for the characteristic detection of singlet oxygen. ABDA reacts with  $^1\text{O}_2$  to produce the corresponding peroxide and leads to a decrease in its characteristic absorption. Therefore, the variation of  $^1\text{O}_2$  production can be detected by monitoring the change of ABDA absorbance. Fig. 2c illustrates a sharp decrease in the absorbance of ABDA within 10 min of the reaction, which indicated that the mixed system produced a large amount of  $^1\text{O}_2$  under 980 nm light excitation. In addition to the ABDA test, 2,2,6,6-tetramethylpiperidine (TEMP) was further employed as a spin trapping agent, and electron spin resonance (ESR) spectroscopy was used to determine the  $^1\text{O}_2$  production. Fig. 2d indicates  $^1\text{O}_2$  characteristic triple peaks 1:1:1 under 980 nm irradiation. This further confirmed the production of a large amount of  $^1\text{O}_2$  by energy transfer process in UCMs under NIR laser irradiation. In addition, the quantum yield ( $\Delta\phi$ ) of  $^1\text{O}_2$  production by UCMs was evaluated. The  $\Delta\phi$  value by methylene blue (MB) was derived to be 0.42 with the  $^1\text{O}_2$  quantum yield calculation formula (Fig. S12, ESI $^\dagger$ ).

### 3.3. Peroxidase-like activity of UCMs

The tumor microenvironment is characterized by hypoxia and a high concentration of  $\text{H}_2\text{O}_2$ . Therefore, the tumor microenvironment may pose limitations for the photodynamic therapy due to the fact that photodynamic type II therapy occurs in the presence of oxygen. The previous studies have demonstrated that Fe(III)-porphyrins exhibit high biocatalytic activity, the




Fig. 2 (a) Upconversion luminescence spectra of the PEI/PVP-UCNPs and the UV-vis absorption spectra of UCMs. (b) Upconversion luminescence spectra of OA-UCNPs (1 mg mL<sup>-1</sup>), PEI/PVP-UCNPs (1 mg mL<sup>-1</sup>) and UCMs (1 mg mL<sup>-1</sup>). (c)  $^1\text{O}_2$  generation under normoxic conditions upon 980 nm laser irradiation (1.5 W cm<sup>-2</sup>). The concentration of UCMs was 200  $\mu\text{g mL}^{-1}$ . (d) ESR spectra of UCMs with different conditions (dark, light: 660 nm laser, NIR: 980 nm laser) upon the addition of TEMP (trapping agent of  $^1\text{O}_2$ ). (e)  $^1\text{O}_2$  generation under different conditions tested by SOSG. (f) Time-dependent generation of  $^1\text{O}_2$  treated with different conditions tested by SOSG. The concentration of  $\text{H}_2\text{O}_2$  was 100  $\mu\text{M}$ .

chelation with  $\text{Fe}^{3+}$  can generate oxygen with  $\text{H}_2\text{O}_2$ .<sup>20,21</sup> In this respect, UCMS may be able to alleviate hypoxic environments and facilitate photodynamic therapy. The capability of UCMS to decompose  $\text{H}_2\text{O}_2$  and produce oxygen was first investigated, and the amount of oxygen produced by UCMS under different conditions was tested using a dissolved oxygen meter. Fig. S13 (ESI<sup>†</sup>) illustrates that UCMS can continuously produce oxygen in the presence of  $\text{H}_2\text{O}_2$  compared to the cases with  $\text{H}_2\text{O}_2$ -only and UCMS-only. Furthermore, the capability of UCMS to produce  $^1\text{O}_2$  under different conditions was examined by using the singlet oxygen sensor green (SOSG) characterization kit. Fig. 2e and f demonstrates that UCMS could produce more singlet oxygen in the presence of  $\text{H}_2\text{O}_2$  under NIR light irradiation. By considering the  $\text{O}_2$ -dependent characteristics of photodynamic type II therapy, UCMS can consume more  $\text{H}_2\text{O}_2$  to generate  $\text{O}_2$  and ameliorate tumor hypoxia and thus to enhance  $^1\text{O}_2$  production. That is to say, the biocatalytic nature of UCMS shows promising potential in improving the efficacy of photodynamic therapy. As nanomaterials for biological applications, it is important to study the stability of UCMS. UCMS in different concentrations were dispersed in PBS, DMEM medium and fetal bovine serum (FBS). Notably, no aggregation of UCMS was observed after two days in PBS, DMEM medium, or FBS (Fig. S14, ESI<sup>†</sup>). Furthermore, the size of UCMS remained largely consistent across the different solutions (Fig. S15, ESI<sup>†</sup>). Based on these observations, it can be concluded that UCMS exhibit commendable stability under different solvent media studied.

### 3.4. *In vitro* cellular uptake and cell toxicity

The photodynamic treatment capability of UCMS to enhance the therapeutic effect was investigated at the cellular level. First, the uptake of UCMS by HepG2 cells was evaluated by using laser confocal microscopy (CLSM) after culturing the cells with UCMS for different times. For subsequent observation, the cells were localized by staining the nuclei with DAPI, and in addition, UCMS could produce red fluorescent signals under 488 nm excitation.<sup>12</sup> According to the CLSM analysis (Fig. S16, ESI<sup>†</sup>), the fluorescence of UCMS in the cell interior was barely observed after 15 min of incubation, and a faint fluorescence could be identified within the cells after 30 min of incubation, which was afterwards significantly enhanced at 60 min. It was seen that the intracellular fluorescence intensity and distribution were almost the same at 60 min and 120 min of incubation, indicating that the cells could engulf UCMS well within 60 min. In addition, the DAPI nuclear localization illustrated that UCMS were taken up by the cells to the cytoplasmic site. After incubating HepG2 cells with different concentrations of UCMS for 24 h, the cell viability was kept at  $>85\%$  at  $200 \mu\text{g mL}^{-1}$  and  $>80\%$  at  $1 \text{ mg mL}^{-1}$  (Fig. 3a). In addition, different concentrations of UCMS were incubated with normal liver cells LX-2 for 24 h. Fig. S17 (ESI<sup>†</sup>) shows that even at the highest concentration of  $200 \mu\text{g mL}^{-1}$ , the viability of LX-2 cells reached 95%. These indicated that UCMS exhibit favorable biocompatibility which may facilitate the subsequent photodynamic therapy of tumors.




Fig. 3 (a) HepG2 cell viability treated with different concentrations of UCMS for 24 h. (b) HepG2 cell viability after incubating with different treatments for 24 h. Data are shown as means  $\pm$  SD.  $n = 3$ .  $^{**}p < 0.01$ ,  $^{***}p < 0.001$ . (c) CLSM images of the produced intracellular  $\text{O}_2$ . After various treatments (control,  $\text{H}_2\text{O}_2$ , UCMS, UCMS +  $\text{H}_2\text{O}_2$ ), HepG2 cells were stained with cell nuclear dye DAPI, and  $[\text{Ru}(\text{dpp})_3]\text{Cl}_2$  were used as the dissolved  $\text{O}_2$  probe. The concentration of  $\text{H}_2\text{O}_2$  was  $100 \mu\text{M}$ . The power density of 980 nm laser was  $1.5 \text{ W cm}^{-2}$  for 10 min. The scale bar indicates  $50 \mu\text{m}$ .

### 3.5. Evaluation of photodynamic therapy in living cells

The effect of photodynamic treatment of UCMS was evaluated (Fig. S18, ESI<sup>†</sup>), with the evaluation of cell viability as analyzed by using CCK-8 assay. With the increase of UCM concentration for cell incubation, the viability of cells after NIR irradiation was gradually decreased. At a concentration level of  $100 \mu\text{g mL}^{-1}$  for UCMS, the cell viability was remarkably decreased to 63.2%. This indicated that UCMS exhibit a significant PDT effect and obvious value-added inhibition on tumor cells. Further studies have found that UCMS may enhance the effects of photodynamic therapy. For examining the capability of UCMS to decompose  $\text{H}_2\text{O}_2$  in cell interior and generate  $\text{O}_2$ ,  $[\text{Ru}(\text{dpp})_3]\text{Cl}_2$  reagent was chosen as an oxygen indicator, and the fluorescence of  $[\text{Ru}(\text{dpp})_3]\text{Cl}_2$  would be quenched by oxygen. The cells were first pretreated with anoxia and incubated in anoxic bags for 12 h. The anoxic cells were then incubated with UCMS. Fig. 3c clearly shows the fluorescence quenching of  $[\text{Ru}(\text{dpp})_3]\text{Cl}_2$  in the cells treated with UCMS, indicating the intracellular decomposition of  $\text{H}_2\text{O}_2$  to produce  $\text{O}_2$ . In addition, the cells pre-incubated with  $\text{H}_2\text{O}_2$  showed complete dye quenching after the addition of UCMS, illustrating the production of more oxygen by the  $\text{H}_2\text{O}_2$ -treated cells with respect to those without incubation with  $\text{H}_2\text{O}_2$ . This observation further demonstrated the capability of  $\text{H}_2\text{O}_2$  consumption by UCMS to produce  $\text{O}_2$ .

The ability of UCMs to enhance photodynamic therapy was investigated by culturing HepG2 cells under hypoxic conditions and by introducing additional H<sub>2</sub>O<sub>2</sub>-treated cells. First, the biocompatibility of H<sub>2</sub>O<sub>2</sub> with cells was studied. The results of Fig. S19 (ESI<sup>†</sup>) showed that cells were still active after 1 mM H<sub>2</sub>O<sub>2</sub> treatment. CCK-8 was used to detect the relative viability of hypoxic cells under different treatments, and the results showed (Fig. 3b) that the relative viability of cells was significantly reduced under near-infrared light irradiation at UCMs concentration of 100 μg mL<sup>-1</sup>. When the cells were treated with H<sub>2</sub>O<sub>2</sub>, the relative viability rate of the cells was further significantly reduced under near-infrared irradiation, indicating that the addition of H<sub>2</sub>O<sub>2</sub> promoted the photodynamic treatment effect of UCMs. It is indirectly proved that UCMs can overcome the hypoxic environment and play a better photodynamic therapeutic effect in the tumor cell microenvironment. To explore the amount of intracellular production of reactive oxygen species (ROS), a common intracellular ROS fluorescent probe, DCFH-DA, was used to detect the production of intracellular ROS in HepG2 cells after different treatments. As shown in Fig. S20 (ESI<sup>†</sup>), UCMs were capable of producing ROS under NIR light irradiation, while in H<sub>2</sub>O<sub>2</sub>-treated cells, UCMs could produce even more ROS under laser irradiation. This further confirmed the aforementioned results for the enhancement of photodynamic therapy.

In addition, further assessment of apoptosis effect by different treatments was performed under CLSM by staining the cells with FDA/PI (Fig. S21, ESI<sup>†</sup>); it was found that the control group and the group treated only with 980 nm laser, UCMs as well as H<sub>2</sub>O<sub>2</sub>, showed almost no cell death (green fluorescence). In contrast, cells treated with UCMs irradiated with NIR showed mostly dead results (red fluorescence). By NIR irradiation of the cells pretreated with H<sub>2</sub>O<sub>2</sub>, virtually only dead cells were observed in the field of view. Meanwhile, the results of flow cytometry in Fig. S22 (ESI<sup>†</sup>) showed that NIR and H<sub>2</sub>O<sub>2</sub>-treated cells were almost killed, which well demonstrated the observations in live-dead cell staining experiments. Collectively, the above studies confirmed that UCMs have the capability to facilitate PDT while overcoming the lack of oxygen in the tumor microenvironment and they are able to utilize the excess H<sub>2</sub>O<sub>2</sub> therein to enhance the PDT treatment effect further.

### 3.6. Evaluation of *in vivo* treatment effect

UCMs have been demonstrated to exhibit excellent photodynamic treatment effect *in vitro*. Herein, their anti-tumor effect *in vivo* was further exploited. The anti-tumor capacity of UCMs was evaluated in detail in BALB/C mice by tail intravenous injection. To further investigate the safety of UCMs on the body, the biodistribution of UCMs was studied with detection by inductively coupled plasma mass spectrometry (ICP-MS) and the levels of yttrium (Y) in the brain, liver, kidneys, spleen, lungs and tumors of the mice were measured at 6 h, 24 h, and 48 h after the injection of UCMs. The experiments indicated that at 6 h after injection, UCMs were found to distribute in all these organs, with the majority identified in kidneys, spleen,




Fig. 4 (a) The relative tumor volume and (b) the body weight of mice bearing HepG2 tumors after various treatments during a 14 day treatment. Data are shown as means  $\pm$  SD;  $n = 3$  mice/group.  $**P < 0.01$ ,  $***P < 0.001$ . (c) The Ki67 staining and ALDH1 staining in the tumor site with different treatments. The concentration of UCMs was 4 mg mL<sup>-1</sup> (100 μL). The power density of 980 nm laser was 1.5 W cm<sup>-2</sup>. The scale bar is 50 μm.

liver and tumors. After 48 h, UCMs were almost completely metabolized in all organs except tumor tissues (Fig. S23, ESI<sup>†</sup>).

Furthermore, to investigate the effect of UCM treatment, the tumor-bearing mice were divided into four groups to receive different treatments. The mice were treated every two days for two weeks, and the variations of tumors as well as body weight were recorded during the treatment period. The tumor volume growth curve analysis showed that the growth of tumors was not inhibited during the 14 days of treatment with PBS and laser. However, tumor growth was significantly inhibited in the group that received UCMs and UCMs + laser treatment (Fig. 4a). Fig. S24 (ESI<sup>†</sup>) demonstrates significant difference in tumor size after 14 days. In addition, the body weight of mice was relatively stable during the treatment period, further indicating negligible biological toxicity and side effects of UCMs (Fig. 4b). Immunohistochemical experiments were performed on each organ after treatment, and the results of H&E staining illustrated that there were no significant changes in the morphology of each tissue in all groups after treatment (Fig. S25, ESI<sup>†</sup>). In addition, the blood routine was performed on the tumor-bearing mice injected intravenously with UCMs, and those hematological indicators presented no discernible differences from the control group (Fig. S26, ESI<sup>†</sup>). Those data indicate the excellent biocompatibility of UCMs in the therapy conditions. Immunohistochemical staining of tumor tissues was performed for Ki67 and ALDH1, with Ki67 as the cell proliferation marker and ALDH1 as a tumor stem cell marker. Fig. 4c indicates that the value-added of tumor cells was inhibited and apoptosis of tumor cells was found after treatment with UCMs and laser. To confirm the capability of UCMs to ameliorate hypoxia in solid tumors, HIF-1 $\alpha$  was selected for immunofluorescence assays of tumors, with the results illustrated in Fig. S27 (ESI<sup>†</sup>). After treatment, the tumors in the PBS group

showed a significant HIF-1 $\alpha$  fluorescence signal (red fluorescence) due to hypoxia, while the characteristic immunofluorescence of HIF-1 $\alpha$  in tumors in the UCMs group decreased dramatically. This was mainly due to the catalytic activity of UCMs, which broke down intracellular H<sub>2</sub>O<sub>2</sub> and produced O<sub>2</sub> in the tumor microenvironment. This further promoted the enhancement efficacy of oxygen-dependent PDT type II *in vivo*. It demonstrated the promising potential antitumor therapeutic effect of UCMs under laser irradiation in the hypoxic tumor environment. The above experimental results clearly confirmed that UCMs have favorable biosafety and anti-tumor therapeutic effects *in vivo*, and furthermore, they may have great prospects for the application in tumor therapy.

## 4. Conclusions

In summary, UCNPs-MOFs (UCMs) nanocomposites have been prepared utilizing a dual-ligand-assisted self-assembly approach. This method generates asymmetric heterostructures composed of UCNPs and Fe(III)-porphyrin MOFs. The nucleation and growth kinetics of PCN-224(Fe) can be meticulously controlled by the dual ligands, *i.e.*, PEI and PVP, that are present on the surface of the functional nanoparticles. The integrated UCMs nanosystem showcases promising optical properties, as the UCNPs undergo an energy transfer with the MOFs. This characteristic endows the UCMs with the ability to activate photodynamically when exposed to near-infrared light. Additionally, UCMs possess the ability to decompose endogenous H<sub>2</sub>O<sub>2</sub> in the tumor microenvironment. The inherent ability of UCMs to self-oxygenate helps overcome the limitations imposed by the tumor microenvironment. This feature promotes the subsequent activation of photodynamic therapy using near-infrared light, significantly enhancing the capability of photodynamic treatment. *In vitro* and *in vivo* studies have demonstrated that UCMs display significant biocatalytic activity and a remarkable PDT effect when driven by near-infrared irradiation. The current work leverages a unique dual-ligand-assisted self-assembly protocol to highlight the immense potential of MOF-based heterostructures in biomedicine. This innovative strategy could pave the way for the integration and construction of more heterostructured nanoplatforms for potential future applications in the field of biomedicine.

## Author contributions

Xinyue Zhang: methodology, investigation, software, writing – original draft, resources. Jiasen Cui: responsible for animal experiment. writing – review & editing. Jinhui Liu: investigation, validation. Xi Chen: responsible for animal experiment. Ming-Li Chen: conceptualization, methodology, writing – review & editing, supervision, funding acquisition. Jianhua Wang: conceptualization, methodology, revising & editing, supervision, funding acquisition.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors appreciate the financial support of the National Natural Science Foundation of China (22274017 and 22074011). Special thanks are due to the Analytical and Testing Center, Northeastern University, for the assistance in instrumental analysis.

## Notes and references

- H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, *Ca-Cancer J. Clin.*, 2021, **71**, 209–249.
- A. S. Thakor and S. S. Gambhir, *Ca-Cancer J. Clin.*, 2013, **63**, 395–418.
- C. J. Allegra, *J. Natl. Cancer Inst.*, 2012, **104**, 961–962.
- G. Yang, X. Sun, J. Liu, L. Feng and Z. Liu, *Adv. Funct. Mater.*, 2016, **26**, 4722–4732.
- X. Li, N. Kwon, T. Guo, Z. Liu and J. Yoon, *Angew. Chem., Int. Ed.*, 2018, **57**, 11522–11531.
- K. Lu, C. He and W. Lin, *J. Am. Chem. Soc.*, 2014, **136**, 16712–16715.
- K. Lu, C. He and W. Lin, *J. Am. Chem. Soc.*, 2015, **137**, 7600–7603.
- G. Li, S. Zhao, Y. Zhang and Z. Tang, *Adv. Mater.*, 2018, **30**, 1800702.
- T. Simon-Yarza, A. Mielcarek, P. Couvreur and C. Serre, *Adv. Mater.*, 2018, **30**, 1707365.
- F. S. Liao, W. S. Lo, Y. S. Hsu, C. C. Wu, S. C. Wang, F. K. Shieh, J. V. Morabito, L. Y. Chou, K. C. Wu and C. K. Tsung, *J. Am. Chem. Soc.*, 2017, **139**, 6530–6533.
- D. Wang, J. Zhou, R. Shi, H. Wu, R. Chen, B. Duan, G. Xia, P. Xu, H. Wang, S. Zhou, C. Wang, H. Wang, Z. Guo and Q. Chen, *Theranostics*, 2017, **7**, 4605–4617.
- J. Park, Q. Jiang, D. Feng, L. Mao and H. C. Zhou, *J. Am. Chem. Soc.*, 2016, **138**, 3518–3525.
- Y. Wang, W. Wu, J. Liu, P. N. Manghnani, F. Hu, D. Ma, C. Teh, B. Wang and B. Liu, *ACS Nano*, 2019, **13**, 6879–6890.
- J. Liu, T. Liu, P. Du, L. Zhang and J. Lei, *Angew. Chem., Int. Ed.*, 2019, **58**, 7808–7812.
- A. I. Minchinton and I. F. Tannock, *Nat. Rev. Cancer*, 2006, **6**, 583–592.
- L. Chudal, N. K. Pandey, J. Phan, O. Johnson, L. Lin, H. Yu, Y. Shu, Z. Huang, M. Xing, J. P. Liu, M. L. Chen and W. Chen, *ACS Appl. Bio Mater.*, 2020, **3**, 1804–1814.
- F. Muhammad, A. Wang, L. Miao, P. Wang, Q. Li, J. Liu, J. Du and G. Zhu, *Langmuir*, 2015, **31**, 514–521.
- H. Chen, J. Tian, W. He and Z. Guo, *J. Am. Chem. Soc.*, 2015, **137**, 1539–1547.
- L. Chudal, N. K. Pandey, J. Phan, O. Johnson, X. Li and W. Chen, *Mater. Sci. Eng., C*, 2019, **104**, 109979.
- M. Huo, L. Wang, Y. Chen and J. Shi, *Nat. Commun.*, 2017, **8**, 357.



- 21 S. Dong, Y. Dong, T. Jia, S. Liu, J. Liu., D. Yang, F. He, S. Gai, P. Yang and J. Lin, *Adv. Mater.*, 2020, **32**, 2002439.
- 22 N. Kheshtchin, S. Arab, M. Ajami, R. Mirzaei, M. Ashourpour, N. Mousavi, N. Khosravianfar, F. Jadidi-Niaragh, A. Namdar, F. Noorbakhsh and J. Hadjati, *Cancer Immunol. Immunother.*, 2016, **65**, 1159–1167.
- 23 Z. Cai, F. Xin, Z. Wei, M. Wu, X. Lin, X. Du, G. Chen, D. Zhang, Z. Zhang, X. Liu and C. Yao, *Adv. Healthcare Mater.*, 2020, **9**, 1900996.
- 24 K. Lu, C. He, N. Guo, C. Chan, K. Ni, R. R. Weichselbaum and W. Lin, *J. Am. Chem. Soc.*, 2016, **138**, 12502–12510.
- 25 G. Lan, K. Ni, Z. Xu, S. S. Veroneau, Y. Song and W. Lin, *J. Am. Chem. Soc.*, 2018, **140**, 5670–5673.
- 26 L. D. Sun, H. Dong, P. Z. Zhang and C. H. Yan, *Annu. Rev. Phys. Chem.*, 2015, **66**, 619–642.
- 27 W. Zheng, P. Huang, D. Tu, E. Ma, H. Zhu and X. Chen, *Chem. Soc. Rev.*, 2015, **44**, 1379–1415.
- 28 J. Zhou, Q. Liu, W. Feng, Y. Sun and F. Li, *Chem. Rev.*, 2015, **115**, 395–465.
- 29 Y. Li, Z. Di, J. Gao, P. Cheng, C. Di, G. Zhang, B. Liu, X. Shi, L. D. Sun, L. Li and C. H. Yan, *J. Am. Chem. Soc.*, 2017, **139**, 13804–13810.
- 30 Y. Shao, B. Liu, Z. Di, G. Zhang, L. D. Sun, L. Li and C. H. Yan, *J. Am. Chem. Soc.*, 2020, **142**, 3939–3946.
- 31 Y. Zhang, F. Wang, C. Liu, Z. Wang, L. Kang, Y. Huang, K. Dong, J. Ren and X. Qu, *ACS Nano*, 2018, **12**, 651–661.
- 32 H. J. Cai, T. T. Shen, J. Zhang, C. F. Shan, J. G. Jia, X. Li, W. S. Liu and Y. Tang, *J. Mater. Chem. B*, 2017, **5**, 2390–2394.
- 33 J. Jiang, Y. Zhao and O. M. Yaghi, *J. Am. Chem. Soc.*, 2016, **138**, 3255–3265.
- 34 A. E. Guller, A. Nadort, A. N. Generalova, E. V. Khaydukov, A. V. Nechaev, I. A. Kornienko, E. V. Petersen, L. Liang, A. B. Shekhter, Y. Qian, E. M. Goldys and A. V. Zvyagin, *ACS Biomater. Sci. Eng.*, 2018, **4**, 3143–3153.
- 35 L. Zhang, D. Jin and M. H. Stenzel, *Biomacromolecules*, 2021, **22**, 3168–3201.
- 36 Y. Zhang, X. Zhu and Y. Zhang, *ACS Nano*, 2021, **15**, 3709–3735.
- 37 T. Wan, W. Li and Z. Chen, *J. Pharm. Biomed. Anal.*, 2021, **199**, 114049.
- 38 L. He, M. Brasino, C. Mao, S. Cho, W. Park, A. P. Goodwin and J. N. Cha, *Small*, 2017, **13**, 1700504.
- 39 L. He, Q. Ni, J. Mu, W. Fan, L. Liu, Z. Wang, L. Li, W. Tang, Y. Liu, Y. Cheng, L. Tang, Z. Yang, Y. Liu, J. Zou, W. Yang, O. Jacobson, F. Zhang, P. Huang and X. Chen, *J. Am. Chem. Soc.*, 2020, **142**, 6822–6832.
- 40 H. Ang and L. Hong, *ACS Appl. Mater. Interfaces*, 2017, **9**, 28079–28088.